PERSON DIRECTORY
Molly O'Shea
Host of Sourcery. Molly O'Shea appears in 41 indexed conversations across Sourcery. This directory brings every appearance, source, TL;DR, digest, and transcript into one searchable feed.
Thrive Capital’s Dr. Nworah Ayogu on Why Neuralink Is More Interesting Than SpaceX
Thrive’s healthcare thesis is that AI may shift bottlenecks from molecule generation to validation, trials, manufacturing, and commercialization.Cadence cites 25% fewer hospitalizations, over-80% more controlled-blood-pressure patients, nearly one-point lower A1C, and $2.5 million in weekly Medicare savings across 100,000+ monitored patients.Neuralink and OpenAI show upside, while clinical processes and manufacturing capacity remain unresolved constraints.
Annie Lamont: $14B Managed, 70+ Exits, 15 IPOs, 7x Midas Investor
Jonathan SiddharthMolly O'Shea
Healthcare AI has crossed O'Shea’s threshold for measurable impact, with biological and chemical models, laboratory robotics and simulations targeting drug development’s high failure rates.After a decade building licenses, networks and care infrastructure, Devoted Health tripled in size, halved operating expenses and significantly increased EBITDA, while China’s rising pharmaceutical research share leaves domestic research and regulatory capacity as risks to monitor.
Race to Save Humanity: Inside $12B Colossal Biosciences & $3.8B Astromech
Colossal’s woolly mice validated mammoth-editing in 30 days, with 100% healthy births and predicted phenotypes.With $635M raised, its screwworm solution could eradicate the problem in six to seven months versus $1.5B in taxpayer spending over eight years, pending permits.Astromec uses evolutionary-genomics AI for drug discovery; another extinct species may arrive within 12 months, but the target remains undisclosed.